BIOLINERX     Print Page  Close Window

SEC filings
F-1
BIOLINERX LTD. filed this Form F-1 on 10/02/2012
Entire Document
 
54

 
 
Developing drugs, conducting clinical trials and commercializing products is expensive and we will need to raise substantial additional funds to achieve our strategic objectives. Although we believe our existing cash resources will be sufficient to fund our projected cash requirements through the second quarter of 2014, we will require significant additional financing in the future to fund our operations. Additional financing may not be available on acceptable terms, if at all. Our future capital requirements will depend on many factors, including:
 
 
the progress and costs of our preclinical studies, clinical trials and other research and development activities;
 
 
the scope, prioritization and number of our clinical trials and other research and development programs;
 
 
the amount of revenues we receive under our collaboration or licensing arrangements;
 
 
the costs of the development and expansion of our operational infrastructure;
 
 
the costs and timing of obtaining regulatory approval of our therapeutic candidates;
 
 
the ability of our collaborators to achieve development milestones, marketing approval and other events or developments under our collaboration agreements;
 
 
the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;
 
 
the costs and timing of securing manufacturing arrangements for clinical or commercial production;
 
 
the costs of establishing sales and marketing capabilities or contracting with third parties to provide these capabilities for us;
 
 
the costs of acquiring or undertaking development and commercialization efforts for any future product candidates;
 
 
the magnitude of our general and administrative expenses;
 
 
any cost that we may incur under current and future licensing arrangements relating to our therapeutic candidates; and
 
 
payments to the OCS.
 
Until we can generate significant continuing revenues, we expect to satisfy our future cash needs through payments received under our collaborations, debt or equity financings, or by out-licensing other product candidates. We cannot be certain that additional funding will be available to us on acceptable terms, or at all.
 
If funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research or development programs or our commercialization efforts.
 
Off-Balance Sheet Arrangements
 
Since inception, we have not entered into any transactions with unconsolidated entities whereby we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities, or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.